Pioglitazone decreases asymmetric dimethylarginine levels in patients with impaired glucose tolerance or type 2 diabetes

Rejuvenation Research

Volumn 16, Issue 5, 2013, Pages 344-351

  Tahara, Nobuhiro ^a   Yamagishi, Sho Ichi ^a   Mizoguchi, Minori ^a   Tahara, Atsuko ^a   Imaizumi, Tsutomu ^a  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; FIBRONECTIN; GLIBENCLAMIDE; GLIMEPIRIDE; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; N(G),N(G) DIMETHYLARGININE; PIOGLITAZONE; TRIACYLGLYCEROL;

ADULT; AGED; ARTERIAL WALL THICKNESS; ARTICLE; BODY WEIGHT; CAROTID ATHEROSCLEROSIS; DEMOGRAPHY; DIET RESTRICTION; DRUG EFFECT; ECHOGRAPHY; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; HUMAN; IMPAIRED GLUCOSE TOLERANCE; INSULIN BLOOD LEVEL; INSULIN SENSITIVITY; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN EXPRESSION; WAIST CIRCUMFERENCE;

AGED; AGED, 80 AND OVER; ARGININE; DIABETES MELLITUS, TYPE 2; FEMALE; FIBRONECTINS; GLUCOSE INTOLERANCE; HUMANS; MALE; MIDDLE AGED; REGRESSION ANALYSIS; SULFONYLUREA COMPOUNDS; THIAZOLIDINEDIONES;

EID: 84886042188     PISSN: 15491684     EISSN: 15578577     Source Type: Journal    
DOI: 10.1089/rej.2013.1434     Document Type: Article

References (43)

1. Yamagishi S, Ueda S, Nakamura K, Matsui T, Okuda S. Role of asymmetric dimethylarginine (ADMA) in diabetic vascular complications. Curr Pharm Des 2008;14:2613-2618.
2. Ueda S, Yamagishi S, Matsumoto Y, Fukami K, Okuda S. Asymmetric dimethylarginine (ADMA) is a novel emerging risk factor for cardiovascular disease and the development of renal injury in chronic kidney disease. Clin Exp Nephrol 2007;11:115-121. (Pubitemid 47012517)
3. Yamagishi S, Matsui T. Nitric oxide, a janus-faced therapeutic target for diabetic microangiopathy-Friend or foe? Pharmacol Res 2011;64:187-194.
4. Tarnow L, Hovind P, Teerlink T, Stehouwer CD, Parving HH. Elevated plasma asymmetric dimethylarginine as a marker of cardiovascular morbidity in early diabetic nephropathy in type 1 diabetes. Diabetes Care 2004;27:765-769. (Pubitemid 38280547)
5. Ishibashi Y, Yamagishi S, Matsui T, et al. Pravastatin inhibits advanced glycation end products (AGEs)-induced proximal tubular cell apoptosis and injury by reducing receptor for AGEs (RAGE) level. Metabolism 2012;61:1067-1072.
6. Ojima A, Ishibashi Y, Matsui T, et al. Glucagon-like Peptide- 1 receptor agonist inhibits asymmetric dimethylarginine generation in the kidney of streptozotocin-induced diabetic rats by blocking advanced glycation end product-induced protein arginine methyltranferase-1 expression. Am J Pathol 2013;182:132-141.
7. Yamagishi S, Matsui T. Soluble form of a receptor for advanced glycation end products (sRAGE) as a biomarker. Front Biosci (Elite Ed) 2010;2:1184-1195.
8. Nakamura K, Yamagishi S, Adachi H, et al. Serum levels of sRAGE, the soluble form of receptor for advanced glycation end products, are associated with inflammatory markers in patients with type 2 diabetes. Mol Med 2007; 13:185-189. (Pubitemid 46944961)
9. Thomas MC, Söderlund J, Lehto M, et al. Soluble receptor for AGE (RAGE) is a novel independent predictor of allcause and cardiovascular mortality in type 1 diabetes. Diabetologia 2011;54:2669-2677.
10. Park HJ, Baek JY, Shin WS, et al. Soluble receptor of advanced glycated endproducts is associated with plaque vulnerability in patients with acute myocardial infarction. Circ J 2011;75:1685-1690.
11. Nakamura T, Sato E, Fujiwara N, et al. Positive association of serum levels of advanced glycation end products and high mobility group box-1 with asymmetric dimethylarginine in nondiabetic chronic kidney disease patients. Metabolism 2009;58:1624-1628.
12. Tahara N, Yamagishi SI, Tahara A, Takeuchi M, Imaizumi T. Asymmetrical dimethylarginine level is independently associated with circulating levels of RAGE and PEDF. Int J Cardiol 2012;doi. 10.1016/j.ijcard.2012.11.070.
13. Papanas N, Maltezos E. Oral antidiabetic agents: Antiatherosclerotic properties beyond glucose lowering? Curr Pharm Des 2009;15:3179-192.
14. Yamagishi S, Nakamura K, Matsui T. Regulation of advanced glycation end product (AGE)-receptor (RAGE) system by PPAR-gamma agonists and its implication in cardiovascular disease. Pharmacol Res 2009;60:174-178.
15. Matsui T, Yamagishi S, Takeuchi M, et al. Nifedipine inhibits advanced glycation end products (AGEs) and their receptor (RAGE) interaction-mediated proximal tubular cell injury via peroxisome proliferator-activated receptor-gamma activation. Biochem Biophys Res Commun 2010;398:326-330.
16. Yamagishi S, Nakamura K, Matsui T. Potential utility of telmisartan, an angiotensin II type 1 receptor blocker with peroxisome proliferator-activated receptor-gamma (PPARgamma)- modulating activity for the treatment of cardiometabolic disorders. Curr Mol Med 2007;7:463-469. (Pubitemid 47244891)
17. Yoshida T, Yamagishi S, Nakamura K, et al. Telmisartan inhibits AGE-induced C-reactive protein production through downregulation of the receptor for AGE via peroxisome proliferator-activated receptor-gamma activation. Diabetologia 2006;49:3094-3099. (Pubitemid 44730314)
18. Wang K, Zhou Z, Zhang M, et al. Peroxisome proliferatoractivated receptor gamma down-regulates receptor for advanced glycation end products and inhibits smooth muscle cell proliferation in a diabetic and nondiabetic rat carotid artery injury model. J Pharmacol Exp Ther 2006;317:37-43.
19. Marx N, Walcher D, Ivanova N, et al. Thiazolidinediones reduce endothelial expression of receptors for advanced glycation end products. Diabetes 2004;53:2662-2668. (Pubitemid 39299276)
20. Erdmann E, Dormandy JA, Charbonnel B, et al. The effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with type 2 diabetes and previous myocardial infarction: results from the PROactive (PROactive 05) Study. J Am Coll Cardiol 2007;49:1772-1780. (Pubitemid 46629127)
21. Mazzone T, Meyer PM, Feinstein SB, et al. Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: A randomized trial. JAMA 2006;296:2572-2581. (Pubitemid 44903861)
22. Nissen SE, Nicholls SJ, Wolski K, et al. Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: The PERISCOPE randomized controlled trial. JAMA 2008;299: 1561-1573. (Pubitemid 351482795)
23. Maeda S, Matsui T, Takeuchi M, et al. Pigment epitheliumderived factor (PEDF) inhibits proximal tubular cell injury in early diabetic nephropathy by suppressing advanced glycation end products (AGEs)-receptor (RAGE) axis. Pharmacol Res 2011;63:241-248.
24. Fukami K, Ueda S, Yamagishi S, et al. AGEs activate mesangial TGF-beta-Smad signaling via an angiotensin II type I receptor interaction. Kidney Int 2004;66:2137-2147. (Pubitemid 41115277)
25. Zhang Y, Zhou X, Krepinsky JC, et al. Association study between fibronectin and coronary heart disease. Clin Chem Lab Med 2006;44:37-42. (Pubitemid 43010643)
26. Miyazaki H, Matsuoka H, Cooke JP, Usui M, Ueda S, Okuda S, et al. Endogenous nitric oxide synthase inhibitor: a novel marker of atherosclerosis. Circulation 1999;99:1141-1146. (Pubitemid 29120084)
27. Tahara N, Kai H, Yamagishi S, et al. Vascular inflammation evaluated by [18F]-fluorodeoxyglucose positron emission tomography is associated with the metabolic syndrome. J Am Coll Cardiol 2007;49:1533-1539. (Pubitemid 46517964)
28. Stühlinger MC, Abbasi F, Chu JW, et al. Relationship between insulin resistance and an endogenous nitric oxide synthase inhibitor. JAMA 2002;287:1420-1426. (Pubitemid 34250505)
29. Scalera F, Martens-Lobenhoffer J, et al. Effect of telmisartan on nitric oxide-asymmetrical dimethylarginine system: Role of angiotensin II type 1 receptor gamma and peroxisome proliferator activated receptor gamma signaling during endothelial aging. Hypertension 2008;51:696-703. (Pubitemid 351301523)
30. Wakino S, Hayashi K, Tatematsu S, et al. Pioglitazone lowers systemic asymmetric dimethylarginine by inducing dimethylarginine dimethylaminohydrolase in rats. Hypertens Res 2005;28:255-262. (Pubitemid 40812611)
31. Wang S, Jiang JL, Hu CP, et al. Relationship between protective effects of rosiglitazone on endothelium and endogenous nitric oxide synthase inhibitor in streptozotocininduced diabetic rats and cultured endothelial cells. Diabetes Metab Res Rev 2007;23:157-164.
32. Petrica L, Vlad A, Petrica M, et al. Pioglitazone delays proximal tubule dysfunction and improves cerebral vessel endothelial dysfunction in normoalbuminuric people with type 2 diabetes mellitus. Diabetes Res Clin Pract 2011;94:22-32.
33. Wang TD, Chen WJ, Cheng WC, et al. Relation of improvement in endothelium-dependent flow-mediated vasodilation after rosiglitazone to changes in asymmetric dimethylarginine, endothelin-1, and C-reactive protein in nondiabetic patients with the metabolic syndrome. Am J Cardiol 2006;98:1057-1062.
34. Kelly AS, Thelen AM, Kaiser DR, et al. Rosiglitazone improves endothelial function and inflammation but not asymmetric dimethylarginine or oxidative stress in patients with type 2 diabetes mellitus. Vasc Med 2007;12:311-318.
35. King DE, Player M, Everett CJ. The impact of pioglitazone on ADMA and oxidative stress markers in patients with type 2 diabetes. Prim Care Diabetes 2012;6:157-161.
36. Mittermayer F, Schaller G, Pleiner J, et al. Rosiglitazone prevents free fatty acid-induced vascular endothelial dysfunction. J Clin Endocrinol Metab 2007;92:2574-2580. (Pubitemid 47037360)
37. Scalera F, Martens-Lobenhoffer J, Bukowska A, et al. Effect of telmisartan on nitric oxide-asymmetrical dimethylarginine system: Role of angiotensin II type 1 receptor gamma and peroxisome proliferator activated receptor gamma signaling during endothelial aging. Hypertension 2008;51:696-703. (Pubitemid 351301523)
38. Wakino S, Hayashi K, Tatematsu S, et al. Pioglitazone lowers systemic asymmetric dimethylarginine by inducing dimethylarginine dimethylaminohydrolase in rats. Hypertens Res 2005;28:255-262. (Pubitemid 40812611)
39. Oz Gul O, Tuncel E, Yilmaz Y, et al. Comparative effects of pioglitazone and rosiglitazone on plasma levels of soluble receptor for advanced glycation end products in type 2 diabetes mellitus patients. Metabolism 2010;59:64-69.
40. Pankov R, Yamada KM. Fibronectin at a glance. J Cell Sci 2002;115(Pt 20):3861-3863. (Pubitemid 35256486)
41. Miyazaki Y, Mahankali A, Matsuda M, et al. Improved glycemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with pioglitazone. Diabetes Care 2001;24:710-719. (Pubitemid 32888853)
42. Hernandez AV, Usmani A, Rajamanickam A, Moheet A. Thiazolidinediones and risk of heart failure in patients with or at high risk of type 2 diabetes mellitus: A meta-analysis and meta-regression analysis of placebo-controlled randomized clinical trials. Am J Cardiovasc Drugs 2011;11:115-128.
43. Ferwana M, Firwana B, Hasan R, et al. Pioglitazone and risk of bladder cancer: A meta-analysis of controlled studies. Diabet Med 2013;doi: 10.1111/dme.12144.